Effect of dapagliflozin on cardiovascular, non-cardiovascular, and undetermined causes of deaths (from Sjöström CD, Jongs N, Chertow GM, Kosiborod M, Hou FF, McMurray JJV, Rossing P, Correa-Rotter R, Kurlyandskaya R, Stefansson BV, Toto RD, Langkilde AM, Wheeler DC; for the DAPA-CKD Trial Committees and Investigators. Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis fromthe DAPA-CKD randomized controlled trial. See pages 1216–1227).